Search results
Results from the WOW.Com Content Network
(Reuters) -GSK CEO Emma Walmsley's total remuneration rose 51% to 12.7 million pounds ($16 million) in 2023, thanks to a big jump in performance-related pay, the British drugmaker's annual report ...
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
British drugmaker GSK cut its forecast for 2024 vaccine sales on Wednesday after quarterly revenue from its blockbuster shingles and respiratory syncytial virus (RSV) jabs missed expectations ...
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. [3] It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins. [4] The company was projected to be a global leader in over the ...
Andrew Witty. Sir Andrew Philip Witty (born 22 August 1964) [1] is a British business executive, who is the chief executive officer (CEO) of UnitedHealth Group. He was the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
Dame Emma Natasha Walmsley DBE (born June 1969) is the chief executive officer (CEO) of GlaxoSmithKline. [1] She succeeded Sir Andrew Witty, who retired in March 2017. [2] Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. [3] She grew up in Barrow-in-Furness, Cumbria, England.
China's largest vaccines company Zhifei will pay British drugmaker GSK 2.5 billion pounds ($3.05 billion) for the exclusive rights to distribute GSK's shingles vaccine in the world's No.2 ...